1
|
Asmaa C, Rachida R, Asma D, Louiza K, Souad C, Leila B, Ali B, Messaoud S, Dalila K, Fethi M, Nawel S, Malika A, Bachira M, Nabila A, Chafia TB, Habiba AAB. TNF-α -308A/G SNP association with kidney allograft rejection in Algerian population: A retrospective case-control study. Transpl Immunol 2023; 81:101927. [PMID: 37683737 DOI: 10.1016/j.trim.2023.101927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Revised: 08/29/2023] [Accepted: 09/05/2023] [Indexed: 09/10/2023]
Abstract
No consensus has been reached regarding the association beween the -308A/G single nucleotide polymorphism (SNP) in the tumor necrosis factor-α gene (TNFA) and kidney allograft rejection (KAR). Our retrospective case-control study aimed to assess the association of the SNP with KAR in Algerian patients who underwent kidney transplantation. The study enrolled 313 Algerian patients: 58 kidney-transplant recipients without rejection events (PWoR); 58 kidney-transplant recipients with at least one rejection event, with or without graft loss (PWR); and 197 healthy individuals (HI). The TNFA -308A/G SNP was genotyped using a real-time polymerase chain reaction. The results demonstrated that, the frequencies of TNFA -308A allele and AA genotype were higher in the PWR than in the HI groups (p = 0.001, OR = 2.26, CI = 1.33-3.77 and p = 0.0004, OR = 5.53, CI-1.89-16.6, respectively). Furthermore, the frequencies were higher among the PWR than among the PWoR groups (p = 0.001, OR = 3.29, CI = 1.56-7.21 and p = 0.0006, OR = 28.26, CI = 1.62-493.2, respectively), particularly among PWR patients with de novo anti-human leukocyte antigens (HLA) antibodies (PG-a-HLA-Ab). However, the frequency of TNFA -308G allele was lower in the PWR group than in the PWoR group (p = 0.001, OR = 0.3, CI = 0.1-0.64) and the HI group (p = 0.001, OR = 0.44, CI = 0.27-0.44). Our results suggest an association of the TNFA -308A/G alleles with KAR in Algerian patients who underwent kidney transplantation. Carriers of TNFA -308A allele who have PG-a-HLA-Ab might have a higher risk, whereas TNFA -308G allele carriers could have a lower risk of KAR. Thus, therapeutic strategies can be adapted to minimize KAR risk in patients who have a genetic proclivity for increased pro-inflammatory TNF-α activity.
Collapse
Affiliation(s)
- Chebine Asmaa
- Cytokine and NO Synthase Team, Cellular and Molecular Biology Laboratory, Biological Sciences Faculty, University of Sciences and Technologies Houari Boumedienne (LBCM-FSB-USTHB), Algiers, Algeria
| | - Raache Rachida
- Cytokine and NO Synthase Team, Cellular and Molecular Biology Laboratory, Biological Sciences Faculty, University of Sciences and Technologies Houari Boumedienne (LBCM-FSB-USTHB), Algiers, Algeria
| | - Djendi Asma
- Transplantation and Immunogenetics Laboratory, Immunology Department, Pasteur Institute of Algeria, Algiers, Algeria
| | - Kaci Louiza
- Histological Analysis Laboratory, Algiers, Algeria
| | - Chelghoum Souad
- Department of Nephrology and Transplantation, Nafissa Hamoud Hospital, Algiers, Algeria
| | - Belkacemi Leila
- Department of Nephrology and Transplantation, Nafissa Hamoud Hospital, Algiers, Algeria
| | - Benziane Ali
- Department of Nephrology and Transplantation, Mohamed Amine Debbaghine Hospital, Algiers, Algeria
| | - Saidani Messaoud
- Department of Nephrology and Transplantation, Asaad Hassani Hospital, Algiers, Algeria
| | - Khemri Dalila
- Department of Nephrology and Transplantation, Mustapha Pacha Hospital, Algiers, Algeria
| | - Meҫabih Fethi
- Transplantation and Immunogenetics Laboratory, Immunology Department, Pasteur Institute of Algeria, Algiers, Algeria
| | - Salhi Nawel
- Transplantation and Immunogenetics Laboratory, Immunology Department, Pasteur Institute of Algeria, Algiers, Algeria
| | - Akachouche Malika
- Transplantation and Immunogenetics Laboratory, Immunology Department, Pasteur Institute of Algeria, Algiers, Algeria
| | - Mechti Bachira
- Transplantation and Immunogenetics Laboratory, Immunology Department, Pasteur Institute of Algeria, Algiers, Algeria
| | - Attal Nabila
- Immunology Department, Pasteur Institute of Algeria, Algiers, Algeria
| | - Touil-Boukoffa Chafia
- Cytokine and NO Synthase Team, Cellular and Molecular Biology Laboratory, Biological Sciences Faculty, University of Sciences and Technologies Houari Boumedienne (LBCM-FSB-USTHB), Algiers, Algeria
| | | |
Collapse
|
2
|
Lopez-Soler RI, Borgia JA, Kanangat S, Fhied CL, Conti DJ, Constantino D, Ata A, Chan R, Wang Z. Anti-vimentin Antibodies Present at the Time of Transplantation May Predict Early Development of Interstitial Fibrosis/Tubular Atrophy. Transplant Proc 2017; 48:2023-33. [PMID: 27569939 DOI: 10.1016/j.transproceed.2016.04.009] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2016] [Accepted: 04/27/2016] [Indexed: 12/15/2022]
Abstract
BACKGROUND Anti-vimentin (a cytoskeletal protein) autoantibodies in renal transplant recipients have been correlated with interstitial fibrosis/tubular atrophy (IFTA). In this study, we examine the association between pretransplantation anti-vimentin antibodies and the subsequent development of IFTA. METHODS Sera obtained before renal transplantation from 97 transplant recipients were analyzed for the presence of anti-vimentin antibodies via Luminex assays to determine the concentration of anti-vimentin antibodies. Results were correlated with findings of IFTA on biopsy as well as graft function and patient and graft survival. RESULTS In our patient population, 56 of 97 patients were diagnosed by biopsy with IFTA 2.9 (±2.1) years after renal transplantation. Patients with IFTA on biopsy had higher mean concentration of anti-vimentin antibodies when compared to patients without IFTA (32.2 μg/mL [3.97-269.12 μg/mL] vs 14.57 μg/mL [4.71-87.81 μg/mL]). The risk of developing IFTA with a concentration of anti-vimentin antibody >15 μg/mL before transplantation was 1.96 (95% CI = 1.38-2.79, P = .011). Patients with elevated anti-vimentin antibody concentrations (>15 μg/mL) at the time of transplantation also had a higher risk of developing IFTA (81.4% vs 41.2%; P < .05). In addition, graft function was worse at 1, 3, and 5 years posttransplantation in patients with elevated concentrations of pretransplantation anti-vimentin antibody. Although there were more graft losses in the IFTA groups (49.12% vs 25.64%, P = .021) and the IFTA patients loss their grafts earlier (4.3 years vs 3.6 years), there was no statistical difference in graft loss rates. CONCLUSIONS Pretransplantation anti-vimentin antibody concentrations >15 μg/mL may be a risk factor for IFTA.
Collapse
Affiliation(s)
- R I Lopez-Soler
- Division of Surgery, Section of Transplantation, Albany Medical Center, Albany, New York.
| | - J A Borgia
- Department of Biochemistry, Rush University Medical Center, Chicago, Illinois; Department of Pathology, Rush University Medical Center, Chicago, Illinois
| | - S Kanangat
- Department of Pathology, Rush University Medical Center, Chicago, Illinois
| | - C L Fhied
- Department of Pathology, Rush University Medical Center, Chicago, Illinois
| | - D J Conti
- Division of Surgery, Section of Transplantation, Albany Medical Center, Albany, New York
| | - D Constantino
- Transplant Immunology Laboratory, Albany Medical College, Albany, New York
| | - A Ata
- Division of Surgery, Section of Transplantation, Albany Medical Center, Albany, New York
| | - R Chan
- Division of Surgery, Section of Transplantation, Albany Medical Center, Albany, New York
| | - Z Wang
- Center For Cardiovascular Sciences, Albany Medical College, Albany, New York
| |
Collapse
|
3
|
Abstract
The sensitization of patients to human leukocyte antigens prior to heart transplantation is increasingly being recognized as an important challenge both before and after the transplant, and the effects of sensitization on clinical outcomes are just beginning to be understood. Many patients are listed with the requirement of a negative prospective or virtual crossmatch prior to accepting a donor organ. This strategy has been associated with both longer waitlist times and higher waitlist mortality. An alternative approach is to transplant across a potentially positive crossmatch while utilizing strategies to decrease the significance of the human leukocyte antigen antibodies. This review will examine the challenges and the impact of sensitization on pediatric patients prior to and following heart transplantation.
Collapse
Affiliation(s)
- Jennifer Conway
- Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Canada
| | - Anne I Dipchand
- Labatt Family Heart Center, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| |
Collapse
|